JMP Securities downgraded Auris Medical Holding AG (NASDAQ:EARS) to Market Perform in a report released today.
- Updated: September 17, 2016
Only yesterday Auris Medical Holding AG (NASDAQ:EARS) traded 1.21% higher at $2.02. The company’s 50-day moving average is $3.03 and its two hundred day moving average is $3.65. With the last stock price down 54.20% relative to the two hundred day average, compared to the S&P 500 Index which has decreased -0.01% over the date range. 414,454 shares of Auris Medical Holding AG exchanged hands, down from ann avg. trading volume of 581,431.
JMP Securities has downgraded Auris Medical Holding AG(NASDAQ:EARS) to Market Perform in a report released Thursday August 18 2016.
On Friday August 19 2016, Needham reported on Auris Medical Holding AG(NASDAQ:EARS) lowered the target price from $11.00 to $5.00 that suggested an upside of 1.33%.
A total of 4 equity analysts have issued a ratings update on EARS. Two firms rate the company a strong buy, two firms rate the stock a buy, 0 firms rate the stock a hold, 0 rate the stock to underperform, and finally 0 brokeragesrate the stock as sell with an average target of $11.75
Auris Medical Holding AG has a one-year low of $1.55 and a 52 week high of $7.96 . The company’s market capitalization is currently $0.0.
About Auris Medical Holding AG (NASDAQ:EARS)
Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration. Its second product candidate, AM-111, is being developed for the treatment of acute sensorineural hearing loss (ASNHL). It intends to conduct over two pivotal Phase III trials in the treatment of idiopathic sudden SNHL (ISSNHL), titled Acute Inner Ear Hearing Loss (HEALOS) and Acute Sudden Sensorineural Hearing Loss Treatment (ASSENT). AM-111 received orphan drug designation for the treatment of ASNHL from the United States Food and Drug Administration, and and the European Union agency. It intends to conduct a Phase II trial in the treatment of surgery-induced hearing loss (REACH).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.